Results13 min readUpdated 2026-04-02

    How Much Weight Can You Lose on Semaglutide? Real Clinical Data

    Clinical trial data and real-world results for semaglutide weight loss. Average results by week, factors affecting outcomes, and realistic expectations.

    What the STEP Trials Tell Us: The Gold Standard Data

    The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program comprises five major Phase 3 trials enrolling over 4,500 participants. These trials represent the most rigorous evidence available for semaglutide's weight loss efficacy and provide the foundation for realistic expectations.

    STEP Trial Weight Loss Results Summary

    STEP-1 (obesity, no diabetes)
    14.9% body weight loss

    68 weeks, semaglutide 2.4mg, n=1,961

    STEP-2 (obesity + type 2 diabetes)
    9.6% body weight loss

    68 weeks, semaglutide 2.4mg, n=1,210

    STEP-3 (intensive behavioral therapy)
    16.0% body weight loss

    68 weeks, semaglutide + intensive counseling

    STEP-4 (maintenance after run-in)
    7.9% additional loss or maintained

    Continued vs switched to placebo after 20 weeks

    STEP-5 (long-term, 2 years)
    15.2% body weight loss

    104 weeks, confirming durability of effect

    The consistency across trials is striking. Whether combined with intensive behavioral therapy (STEP-3) or standard care, semaglutide reliably produces 10–16% weight loss. The addition of structured lifestyle intervention adds only modestly to the pharmacological effect alone.

    Week-by-Week Weight Loss Timeline

    Weight loss on semaglutide is not linear. It follows a predictable pattern tied to the dose escalation schedule and the medication's accumulating effect on appetite regulation.

    Weeks 1–4 (0.25mg starter dose)

    1–3 lbs

    Appetite begins to decrease but weight loss is modest. Many patients notice reduced hunger and food cravings. GI side effects most likely during this phase.

    Month 2–3 (0.5mg–1mg)

    4–8 lbs cumulative

    Appetite suppression becomes more pronounced. Food portions decrease naturally. The concept of 'food noise' (constant thoughts about food) begins to quiet.

    Month 4–6 (1.7mg–2.4mg)

    12–20 lbs cumulative

    The most active weight loss phase. At full dose, patients often lose 1–2 lbs per week consistently. GI side effects have typically stabilized.

    Month 7–12 (2.4mg maintenance)

    20–35 lbs cumulative

    Weight loss continues but rate begins to slow as body weight decreases. Still the period of maximum total loss for most patients.

    Beyond 12 months

    Plateau and maintenance

    Most patients reach a new set point around 12–18 months. Maintenance of weight loss is the primary goal with continued treatment.

    Real Weight Loss by Starting Body Weight

    Percentage-based weight loss results translate to very different absolute numbers depending on your starting weight. Here is what 15% average weight loss looks like across different starting weights:

    Starting Weight
    15% Loss (avg)
    20% Loss (high end)
    180 lbs
    27 lbs
    36 lbs
    220 lbs
    33 lbs
    44 lbs
    260 lbs
    39 lbs
    52 lbs
    300 lbs
    45 lbs
    60 lbs
    350 lbs
    52 lbs
    70 lbs

    Factors That Affect Your Results

    Individual variation in semaglutide response is substantial. Understanding what drives better or worse outcomes can help you optimize your treatment.

    Dose achieved

    High Impact

    Patients who reach and maintain 2.4mg lose significantly more than those who stay at lower doses due to side effects. Slow titration to maximize dose tolerability is important.

    Dietary quality

    High Impact

    Semaglutide reduces appetite but does not change what you eat. Patients who shift toward higher protein, lower ultra-processed food diets see substantially better results.

    Presence of type 2 diabetes

    Moderate Impact

    T2D patients typically lose 5–6% less weight than non-diabetic patients on the same dose, reflecting metabolic differences in insulin signaling and GLP-1 receptor sensitivity.

    Resistance training

    Moderate Impact

    Exercise adds modest additional weight loss, but resistance training is crucial for preserving muscle mass during GLP-1-induced weight loss, which affects long-term metabolism.

    Sleep quality

    Moderate Impact

    Poor sleep elevates cortisol and ghrelin, both of which can partially counteract semaglutide's appetite-suppressing effects. 7–9 hours per night supports better outcomes.

    Concurrent medications

    Variable Impact

    Certain antidepressants (mirtazapine, paroxetine), antipsychotics, steroids, and insulin can significantly blunt weight loss response. Review all medications with your provider.

    Clinical Benchmarks: What Counts as Success?

    In obesity medicine, weight loss is assessed at multiple clinical thresholds, each associated with specific health benefits:

    ≥5% weight loss~90% of patients achieve this

    Improvement in blood pressure, triglycerides, fasting glucose; reduced NAFLD progression

    ≥10% weight loss~75% of patients achieve this

    Significant improvement in glycemic control, sleep apnea, joint pain, cardiovascular risk

    ≥15% weight loss~50% of patients achieve this

    Diabetes remission possible, major improvements in metabolic syndrome, reduced cardiac risk

    ≥20% weight loss~32% of patients achieve this

    Outcomes approaching those of bariatric surgery for metabolic endpoints

    For comparison with tirzepatide outcomes, see our article how much weight can you lose on tirzepatide.

    Managing Plateaus and Optimizing Long-Term Results

    Weight loss plateaus are a normal part of GLP-1 therapy, not a sign of failure. Understanding why they happen and how to respond is critical for long-term success.

    A plateau occurs when the body's energy expenditure adapts down to match reduced caloric intake. The body is highly efficient at defending a set point, even on medication. This is not a medication failure — it reflects normal physiology.

    • Ensure you are at the highest tolerated dose before concluding you have plateaued
    • Reassess dietary protein intake — increasing to 0.7–1g per lb body weight often breaks plateaus
    • Add or increase resistance training to prevent muscle loss and maintain metabolic rate
    • Review sleep and stress — chronic stress can completely stall GLP-1-mediated weight loss
    • If plateaued at full dose for 3+ months with 5% or less total loss, consider switching to tirzepatide

    For a month-by-month detailed breakdown, see semaglutide results timeline.

    Frequently Asked Questions

    How much weight does the average person lose on semaglutide?

    In the STEP-1 clinical trial — the largest and most rigorous study — participants on semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks. For a person starting at 230 lbs, that equals approximately 34 lbs. Real-world studies typically show slightly lower results (10–12%) due to less strict adherence and dose escalation, but still represent clinically meaningful weight loss.

    How fast does semaglutide work for weight loss?

    Weight loss begins in the first month, though initial results are modest. Typical timeline: Month 1: 2–4 lbs (appetite begins to decrease); Month 3: 8–12 lbs cumulative; Month 6: 15–20 lbs cumulative; Month 12: 25–35 lbs cumulative (at full 2.4mg dose). The rate of loss is fastest between months 3–9 when at maximum dose, then slows as the body approaches a new set point.

    Does the semaglutide dose affect how much weight you lose?

    Yes, there is a clear dose-response relationship. STEP trial data shows: 0.5mg (low dose): ~6% weight loss; 1mg: ~10% weight loss; 2.4mg (full obesity dose): ~15% weight loss. This is why dose titration over 16–20 weeks is standard — starting at 0.25mg and escalating every 4 weeks allows the body to adjust while working toward the most effective dose.

    Does semaglutide work if you have type 2 diabetes?

    Yes, but results are somewhat lower than in non-diabetic patients. The STEP-2 trial (semaglutide in people with type 2 diabetes) showed 9.6% weight loss at 2.4mg, compared to 14.9% in STEP-1 (no diabetes). This difference occurs because diabetes impairs some of the metabolic pathways that GLP-1 activates. Still, 9.6% weight loss in a diabetic population with simultaneous A1c improvement represents an excellent clinical outcome.

    Why am I not losing weight on semaglutide?

    Common reasons for suboptimal weight loss include: being at a sub-therapeutic dose (not yet at 2.4mg), insufficient time on medication (major losses often come after month 3), dietary habits not changing alongside medication, insufficient sleep or high stress (which increase cortisol and counteract weight loss), hypothyroidism or other hormonal conditions, and certain medications (antidepressants, antipsychotics, steroids) that cause weight gain. Discuss with your provider if you've been at full dose for 12+ weeks with less than 5% weight loss.

    What happens when semaglutide weight loss stops (plateau)?

    Weight loss plateaus are normal and expected, typically occurring after 9–12 months of treatment. At this point the body has adapted its energy expenditure to match intake at the new lower level. Strategies to overcome a plateau include: ensuring you're at the maximum tolerated dose, reassessing dietary composition (protein, fiber, calorie density), adding or increasing resistance training, reviewing medications that may blunt response, and considering switching to tirzepatide for patients who haven't met their goals.

    How much weight can you lose per week on semaglutide?

    During the most active weight loss phase (months 3–9 at full dose), patients typically lose 0.5–1.5 lbs per week on average. This rate varies significantly week to week and is not linear. The first few months at lower doses produce slower loss (0.25–0.5 lbs/week). Weight loss slows as you approach your goal weight. Expecting steady weekly loss every week is unrealistic — the overall monthly trend matters more than any individual week.

    Medical Disclaimer: Individual weight loss results on semaglutide vary significantly. The figures presented reflect clinical trial averages and may not represent your personal outcomes. Semaglutide is a prescription medication. Consult a qualified healthcare provider for personalized guidance on whether semaglutide is appropriate for you and what results to expect based on your health profile.

    Sources & References

    1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989–1002. (STEP-1)
    2. Davies M, et al. "Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2)." Lancet. 2021;397(10278):971–984.
    3. Wadden TA, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3)." JAMA. 2021;325(14):1403–1413.
    4. Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4)." JAMA. 2021;325(14):1414–1425.
    5. Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nat Med. 2022;28:2083–2091.
    6. Kushner RF, et al. "Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials." Obesity. 2020;28(6):1050–1061.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 2, 2026

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Was this article helpful?

    Keep Reading

    See what results to expect each week on semaglutide. Quick timeline from week 1 to month 6 with average weight loss.

    Women in STEP trials lost an average of 15% body weight over 68 weeks. Explore what results actually look like, the month-by-month timeline, and factors that affect outcomes.

    SURMOUNT-1 participants lost up to 22.5% body weight at 72 weeks. See the full dose-response breakdown and realistic timeline for your starting weight.

    Getting a GLP-1 prescription online takes as little as 24-48 hours through telehealth. Here's a step-by-step guide to eligibility, the process, and what to expect.